medCPU, Inc., a healthcare enterprise clinical decision support solution, announced that it closed an $8 million financing round, consisting of $5 million series B-2 equity and $3 million in debt financing. The equity round was led by Merck Global Health Innovation Fund and New Richmond Ventures, and debt financing was provided by Silicon Valley Bank. The company will utilize the additional capital to enable medCPU to continue to assert its leadership position in the dynamic clinical decision support marketplace.
How It Works
medCPU sees the complete clinical picture of each patient, from history though present encounters. The medCPU Advisor™, medCPU’s enterprise platform technology, acquires and processes both structured and unstructured data immediately as it is entered into a clinician’s Electronic Medical Record (EMR) system. The technology then assesses the data against best practice modules to provide the clinician with a holistic view of their patient and to ultimately provide highly accurate, real-time, reliable prompts at the point-of-care.
The platform relies on more than simplistic “if/then” rules to accurately identify deficiencies in documentation and care. It prompts clinical staff at the right moment with precise, reliable and accurate suggestions for improved care.
To meet the needs of different specialized health care organizations, medCPU delivers a wide range of customizable clinical and compliance decision support solutions, including modules for Obstetrics, Spine, Stroke, CHF, COPD, Value Based Purchasing, DRG’s, ICD-10, VTE Prophylaxis, Population Health, and in partnership with ILÚM Health Solutions™ (a subsidiary of Merck & Co., Inc. Kenilworth, NJ) is developing modules for Infectious Diseases such as Sepsis, Pneumonia and Urinary Tract Infection that also enable comprehensive Antimicrobial Stewardship.
“Our technology is already being used by over 20,000 clinicians and a number of leading healthcare providers,” added Ms. Ben-Yehuda. “This financing will help us to continue to grow our market share. We are excited about facilitating the move beyond antiquated, evidence-based reference tools to a new era of clinical decision support.”
